Pulmonary hypertension in heart failure

J Card Fail. 2010 Jun;16(6):461-74. doi: 10.1016/j.cardfail.2010.01.003. Epub 2010 Apr 3.

Abstract

Background: Pulmonary hypertension occurs in 60% to 80% of patients with heart failure and is associated with high morbidity and mortality.

Methods and results: Pulmonary artery pressure correlates with increased left ventricular end-diastolic pressure. Therefore, pulmonary hypertension is a common feature of heart failure with preserved as well as reduced systolic function. Pulmonary hypertension is partially reversible with normalization of cardiac filling pressures. Pulmonary vasculature remodeling and vasoconstriction create a second component, which does not reverse immediately, but has been shown to improve with vasoactive drugs and especially with left ventricular assist devices.

Conclusion: Many drugs used for idiopathic pulmonary arterial hypertension are being considered as treatment options for heart failure-related pulmonary hypertension. This is of particular significance in the heart transplant population. Randomized clinical trials with interventions targeting heart failure patients with elevated pulmonary artery pressure would be justified.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Cardiotonic Agents / therapeutic use
  • Endothelin Receptor Antagonists
  • Heart Failure / complications
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Heart Transplantation*
  • Heart-Assist Devices*
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / physiopathology
  • Nitric Oxide / administration & dosage
  • Nitric Oxide / therapeutic use
  • Phosphodiesterase Inhibitors / therapeutic use
  • Prostaglandins / therapeutic use
  • Risk Factors
  • Stroke Volume
  • Vascular Resistance*
  • Vasodilator Agents / therapeutic use
  • Ventricular Function, Left

Substances

  • Adrenergic beta-Antagonists
  • Antihypertensive Agents
  • Cardiotonic Agents
  • Endothelin Receptor Antagonists
  • Phosphodiesterase Inhibitors
  • Prostaglandins
  • Vasodilator Agents
  • Nitric Oxide